FDA Grants DS-8201 Breakthrough Designation for HER2+ Breast Cancer

August 29, 2017 – The investigational HER2-targeting antibody-drug conjugate DS-8201 has received an FDA breakthrough therapy designation for the treatment of patients with HER2-positive, locally advanced, or metastatic breast cancer who have been treated with trastuzumab and pertuzumab and have disease progression after ado-trastuzumab emtansine (T-DM1). According to the manufacturer of DS-8201, Daiichi Sankyo, the antibody-drug conjugate is composed of … (leggi tutto)